ArticleScience advances2022
Integrative molecular roadmap for direct conversion of fibroblasts into myocytes and myogenic progenitor cells.
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Designed Minibinders Rewire Receptor Signaling to Enable Functional Human Myogenic Reprogramming.bioRxiv : the preprint server for biology · 2026Article
- Emerging roles of epigenetics in the pathogenesis of sarcopenia.Epigenomics · 2026Review
- Skeletal muscle reprogramming in peripheral nerve injury: mechanisms, therapeutic roles, and complication management.Experimental biology and medicine (Maywood, N.J.) · 2026Review
- Chemical reprogramming of fibroblasts into retinal pigment epithelium cells for vision restoration.Nature communications · 2025Article
- Prolonged Cell Encapsulation and Gravity-independent Filamented Light Biofabrication of Muscle Constructs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cell biomechanics on muscle atrophy: from intricate mechanisms to therapeutic frontiers.Annals of medicine · 2025Review
- MYOD represses gene expression from non-E-box motifs.Genes & development · 2025Article
- Filamented Light (FLight) Bioprinting of Mini-Muscles with Self-Renewal Potential.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Enhanced Media Optimize Bovine Myogenesis in 2D and 3D Models for Cultivated Meat Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Fibrillin-1 G234D mutation in the hybrid1 domain causes tight skin associated with dysregulated elastogenesis and increased collagen cross-linking in mice.Matrix biology : journal of the International Society for Matrix Biology · 2025Article
- E-box independent chromatin recruitment turns MYOD into a transcriptional repressor.bioRxiv : the preprint server for biology · 2024Article
- Optimisation of cell fate determination for cultivated muscle differentiation.Communications biology · 2024Article
- The Metabolic Syndrome, a Human Disease.International journal of molecular sciences · 2024Review
- A Self-Renewing Biomimetic Skeletal Muscle Construct Engineered using Induced Myogenic Progenitor Cells.Advanced functional materials · 2024Article
- Transgene-free direct conversion of murine fibroblasts into functional muscle stem cells.NPJ Regenerative medicine · 2023Article
- Review
- CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.Stem cell reports · 2022Article
- Temporal Transcriptomics Leads From Discovery to in Vivo Validation: COL4A3/COL4A6/ COL4A5 and ITGA8 as Novel Arthrofibrosis Biomarkers in Post-traumatic Joint Contracture.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transient MyoD overexpression in concert with small molecule treatment reprograms mouse fibroblasts into induced myogenic progenitor cells (iMPCs). However, the molecular landscape and mechanisms orchestrating this cellular conversion remain unknown. Here, we undertook an integrative multiomics approach to delineate the process of iMPC reprogramming in comparison to myogenic transdifferentiation mediated solely by MyoD. Using transcriptomics, proteomics, and genome-wide chromatin accessibility assays, we unravel distinct molecular trajectories that govern the two processes. Notably, only iMPC reprogramming is characterized by gradual up-regulation of muscle stem cell markers, unique signaling pathways, and chromatin remodelers in conjunction with exclusive chromatin opening in core myogenic promoters. In addition, we determine that the Notch pathway is indispensable for iMPC formation and self-renewal and further use the Notch ligand Dll1 to homogeneously propagate iMPCs. Collectively, this study charts divergent molecular blueprints for myogenic transdifferentiation or reprogramming and underpins the heightened capacity of iMPCs for capturing myogenesis ex vivo.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.